VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Biran Discusses Doublets Versus Triplets in Myeloma

Noa Biran, MD
Published: Friday, Mar 30, 2018



Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Biran says that in the newly diagnosed setting, triplet therapy is better than doublet therapy, both in the transplant-eligible and transplant-ineligible patients. Triplets have shown very rapid and deep responses in these patients, which usually translates into a longer duration of remission, explains Biran.

The SWOG S0777 trial, which evaluated bortezomib (Velcade) with lenalidomide (Revlimid) and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant, showed a longer progression-free survival and overall survival in patients who received the triplet. Biran says that these findings show that it is important to keep those who are ineligible for transplant on a triplet regimen.


Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Biran says that in the newly diagnosed setting, triplet therapy is better than doublet therapy, both in the transplant-eligible and transplant-ineligible patients. Triplets have shown very rapid and deep responses in these patients, which usually translates into a longer duration of remission, explains Biran.

The SWOG S0777 trial, which evaluated bortezomib (Velcade) with lenalidomide (Revlimid) and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant, showed a longer progression-free survival and overall survival in patients who received the triplet. Biran says that these findings show that it is important to keep those who are ineligible for transplant on a triplet regimen.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x